Αποτελέσματα Αναζήτησης
21 Αυγ 2023 · Allegra-D (fexofenadine and pseudoephedrine) is used to treat sneezing, hives, runny or stuffy nose and other symptoms of allergies. Includes Allegra-D side effects, interactions and indications.
Discover the dual-action formula of Allegra-D that offers comprehensive relief from seasonal allergies and congestion. Dive into the science of its active ingredients, Fexofenadine HCl and Pseudoephedrine, and learn how they work in synergy to alleviate bothersome symptoms.
12 Ιουλ 2022 · Allegra -D (fexofenadine hcl and pseudoephedrine hcl) is a combination of an antihistamine and a decongestant used to treat sneezing, cough, runny or stuffy nose, itchy or watery eyes, hives, skin rash, itching, and other symptoms of allergies and the common cold. Allegra-D is available in generic form and over-the-counter.
The active ingredient in Allegra®-D is pseudoephedrine (PSE) which is clinically proven to be effective in combating nasal congestion with the most powerful decongestion ingredient.* Get all-day relief from tough allergy and congestion symptoms with Allegra-D ® 24 Hour Tablets.
25 Μαρ 2024 · Fexofenadine hydrochloride, one of the active ingredients of ALLEGRA-D 12 HOUR, is a histamine H 1 -receptor antagonist with the chemical name (±)-4- [1-hydroxy-4- [4- (hydroxydiphenylmethyl)-1-piperidinyl]-butyl]-α,α-dimethyl benzeneacetic acid hydrochloride and the following chemical structure:
25 Μαρ 2024 · Fexofenadine hydrochloride, one of the active ingredients of ALLEGRA-D 24 HOUR, is a histamine H 1 -receptor antagonist with the chemical name (±)-4- [1-hydroxy-4- [4- (hydroxydiphenylmethyl)-1-piperidinyl]-butyl]-α, α-dimethyl benzeneacetic acid hydrochloride and the following chemical structure:
12 Ιουλ 2022 · Allegra-D 24 Hour (fexofenadine hcl 180 and pseudoephendrine hcl 240) is a combination of an antihistamine and a decongestant used to treat sneezing, cough, runny or stuffy nose, itchy or watery eyes, hives, skin rash, itching, and other symptoms of allergies and the common cold.
